Isotretinoin 20 mg and 40 mg: U.S. Product and iPLEDGE Guide
Isotretinoin is a prescription medication in the United States and is subject to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). It is not an over-the-counter product.
Current U.S. isotretinoin products
Isotretinoin is the active ingredient. FDA notes that U.S. isotretinoin has been marketed under several brand names, including Absorica, Absorica LD, Claravis, Amnesteem, Myorisan and Zenatane, and that the former brand name Accutane is still sometimes used colloquially. Current DailyMed records also show generic isotretinoin capsules under ANDAs from multiple manufacturers.
A current Aurobindo Pharma label updated in September 2026 lists isotretinoin capsules in 20 mg, 30 mg and 40 mg strengths. A current Actavis/Teva-related label includes 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strengths. This illustrates why “isotretinoin 20 mg” or “40 mg” identifies only part of the product.
Product differences can matter
Different isotretinoin products can have different formulations and bioavailability. Current labeling specifically warns that some isotretinoin products are not substitutable with Absorica LD because bioavailability and dosage differ. A patient should therefore verify the exact product rather than assuming that every capsule containing isotretinoin is interchangeable solely by milligram strength.
Manufacturer, NDC, capsule appearance and formulation are appropriate pharmacy-verification questions. A foreign or unverified product listing should not be treated as equivalent to an FDA-approved U.S. product just because it uses the word isotretinoin.
Prescription status and iPLEDGE REMS
FDA describes isotretinoin as a prescription drug for severe recalcitrant nodular acne and states that, because of its high teratogenic risk, approved isotretinoin is distributed under the iPLEDGE REMS. The current labels contain a boxed warning for embryo-fetal toxicity and contraindication in pregnancy.
FDA approved modifications to iPLEDGE in 2026 and announced November 15, 2026 as the implementation date for the system changes. FDA also described enforcement discretion regarding certain pregnancy-testing requirements during the transition. iPLEDGE requirements are time-sensitive, so patients, prescribers and pharmacies should rely on the current FDA and iPLEDGE instructions.
Dosing and treatment remain individualized
The correct isotretinoin dose and treatment course depend on patient-specific factors and the prescriber’s plan. Dose, cumulative exposure, course length and retreatment decisions require clinical guidance, along with review of the psychiatric, laboratory, pregnancy-prevention and drug-interaction warnings in the full labeling.
Access and cost questions
Product access can involve both a valid prescription and iPLEDGE requirements. Insurance coverage, prior authorization, pharmacy participation, manufacturer and strength can affect the dispensing process and cost. A useful price comparison should identify the exact product and date.
Contact the pharmacy to confirm current availability, product identity and coverage for a specific prescription.
iPLEDGE is part of access, not an optional add-on
Unlike many ordinary prescription products, isotretinoin access is tied to a shared REMS program. The FDA describes iPLEDGE as applying to all FDA-approved isotretinoin. That means product access cannot be reduced to “does a pharmacy have 20 mg or 40 mg capsules?” The patient, prescriber and pharmacy requirements in the current program also matter.
The 2026 program modifications are time-sensitive. FDA approved changes in February 2026 and later announced November 15, 2026 as the implementation date. Patients, prescribers and pharmacies should rely on the current FDA and iPLEDGE instructions for the requirements in effect at the time of treatment and dispensing.
Brand names do not erase formulation differences
The former Accutane name is still widely recognized, but current U.S. isotretinoin products include several other brands and generics. Some formulations have bioavailability differences significant enough for labeling to warn against substitution. Exact product identity is therefore more important here than using “Accutane” as a generic nickname for the entire category.
For broader patient-facing information, see Medication & Pharmacy Resources.